Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome

被引:141
|
作者
Ehrmann, DA
Kasza, K
Azziz, R
Legro, RS
Ghazzi, MN
机构
[1] Univ Chicago, Med Ctr, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Med Ctr, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA
[4] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA 17033 USA
[5] Pfizer Pharmaceut Inc, Ann Arbor, MI 48105 USA
来源
关键词
D O I
10.1210/jc.2004-0229
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Racial origin and family history of type 2 diabetes impact upon the risk of developing impaired glucose tolerance (IGT) and type 2 diabetes, both of which are common in women with polycystic ovary syndrome (PCOS). We examined the effects of race and family history of type 2 diabetes on the risk of IGT and type 2 diabetes in a large cohort of women with PCOS. Data obtained at baseline were analyzed from 408 premenopausal women with PCOS. Multivariate linear regression models were used to assess the impact of race (white, black, and other) and family history of type 2 diabetes on body mass index, waist circumference, and waist to hip ratio; glycemic measures (glucose and insulin levels obtained during a standard 75-g oral glucose tolerance test, fasting glucose to insulin ratio, and homeostasis model assessment model of insulin resistance derived from fasting levels of glucose and insulin), hemoglobin A(1c), and SHBG, and dehydroepiandrosterone sulfate levels. Sixteen (4%) of the 408 patients had type 2 diabetes, 94 (23%) had IGT, and the remaining 298 (73%) had normal glucose tolerance. A history of type 2 diabetes in either parent (FHxPOS) was present in seven (44%) of the 16 diabetic women with PCOS, 37 (39%) of the 94 women with IGT, and 62 (21%) of those with normal glucose tolerance (P < 0.01, by chi(2) test). The prevalences of IGT and type 2 diabetes were significantly higher in FHxPOS PCOS women compared with FHxNEG PCOS women, IGT evident in 37 (35%) FHxPOS compared with 57 (19%) FHxNEG women, and type 2 diabetes evident in seven (7%) FHxPOS compared with nine (3%) FHxNEG women. Among the 392 nondiabetic subjects, after adjustment for the effects of race, FHxPOS differed significantly from FHxNEG patients in having a higher mean waist to hip ratio, hemoglobin A(1c) level, 2-h glucose level, fasting glucose and insulin levels, glucose to insulin ratio, homeostasis model assessment model of insulin resistance, and areas under the glucose and insulin curves during the oral glucose tolerance test. A family history of type 2 diabetes was present with a significantly greater frequency among women with PCOS who had IGT or type 2 diabetes compared with those with normal glucose tolerance. Conversely, a family history of type 2 diabetes in a first-degree relative was associated with a significantly higher risk for IGT or type 2 diabetes in women with PCOS. Even among nondiabetic women with PCOS, a positive family history of type 2 diabetes was strongly associated with metabolic characteristics associated with an increased risk for type 2 diabetes. Finally, the fasting glucose concentration was poorly associated with 2-h glucose concentrations among PCOS women with IGT, suggesting that the fasting glucose concentration is inadequate to predict the presence of IGT in PCOS.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [21] The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
    Kakoly, Nadira S.
    Earnest, Arul
    Teede, Helena J.
    Moran, Lisa J.
    Joham, Anju E.
    [J]. DIABETES CARE, 2019, 42 (04) : 560 - 567
  • [22] Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome
    Galazis, Nicolas
    Afxentiou, Thalia
    Xenophontos, Mikalena
    Diamanti-Kandarakis, Evanthia
    Atiomo, William
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (02) : R33 - R43
  • [23] The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome
    Jamilian, Mehri
    Asemi, Zatollah
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (09): : 3386 - 3394
  • [24] Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes mellitus
    Peppard, HR
    Marfori, J
    Iuorno, MJ
    Nestler, JE
    [J]. DIABETES, 2001, 50 : A481 - A481
  • [25] Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome
    Glintborg, Dorte
    Kolster, Naja Due
    Ravn, Pernille
    Andersen, Marianne Skovsager
    [J]. BIOMEDICINES, 2022, 10 (06)
  • [26] Prevalence of polycystic ovary syndrome in reproductive-aged women with type 2 diabetes
    Amini, Massoud
    Horri, Negar
    Farmani, Mahboubeh
    Haghighi, Sassan
    Sattari, Ghoshtasb
    Pornaghshband, Zahra
    Aminorroaya, Ashraf
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (08) : 423 - 427
  • [28] Insulin resistance and beta cell function in polycystic ovary syndrome:: the influence of family history of type 2 diabetes mellitus
    Vrbikova, J.
    Hill, M.
    Bendlova, B.
    Vondra, K.
    Grimmichova, T.
    Pacini, G.
    [J]. DIABETOLOGIA, 2007, 50 : S325 - S326
  • [29] Effects of Metabolic Syndrome on Pregnancy Outcomes in Women Without Polycystic Ovary Syndrome
    Li, Siyuan
    Ma, Shuxin
    Yao, Xiangyi
    Liu, Peihao
    [J]. JOURNAL OF THE ENDOCRINE SOCIETY, 2024, 8 (10)
  • [30] Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus
    Codner, Ethel
    Escobar-Morreale, Hector F.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1209 - 1216